Clinical study over a period of at least 6 months to an individualized strength and endurance training in COPD patients in Marburger

Clinical study over a period of at least 6 months to an individualized strength and endurance training in COPD patients in Marburger - IT vs. CG by ambulatory COPD rehabilitation

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00006842

Enrollment

Registered

2014-10-27

Start date

2014-10-31

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J44.8

Interventions

Group 1: Individualized Training: The patients in this group participate in an individualized program. The program consists of endurance and strength training, as indicated by the joint statement of t

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients diagnosed with COPD, patients of stage I - IV or AD (according to GOLD classification)

Exclusion criteria

Exclusion criteria: Regard to acute pathological cardiac events (e.g. heart attack), comorbidities such as heart failure (NYHA III and IV), congestive heart failure, high blood pressure (> 220/120 mmHg), severe mental illness, cognitive impairments, limitations of the musculoskeletal system, which make a training impossible, neurological diseases that affect the training and implementation, acute exacerbations, acute inflammation / infection

Design outcomes

Primary

Measure	Time frame
Exercise capacity as measured by 6-minute walk test before and after 3- and 6-month treatment phase for the individualized training group and before and after 3 months in the control group	—

Secondary

Measure	Time frame
Following parameters will be measured in the individualized training group at baseline, 3- and 6-month after treatment phase and before the start and after 3 months in the control group: 1. quality of life (SGRQ, CAT score, HADS) 2. Physical fitness (endurance performance (bicycle ergometer tests)) 3. lung function (Spirometire) 4. Systemic inflammation (serum concentration of inflammatory markers) 5. breath condensate (EBC) 6. laboratory parameters (muscular function) 7. left/right ventricular function 8. bone turnover markers	—

Measure

Time frame

Following parameters will be measured in the individualized training group at baseline, 3- and 6-month after treatment phase and before the start and after 3 months in the control group: 1. quality of life (SGRQ, CAT score, HADS) 2. Physical fitness (endurance performance (bicycle ergometer tests)) 3. lung function (Spirometire) 4. Systemic inflammation (serum concentration of inflammatory markers) 5. breath condensate (EBC) 6. laboratory parameters (muscular function) 7. left/right ventricular function 8. bone turnover markers

—

Countries

Germany

Contacts

Public ContactUrsula Boas

Universitätsklinikum Giessen und Marburg Innere Medizin, Pneumologie

boasu@med.uni-marburg.de06421 - 5863326

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026